Table 3.

Upcoming cardiovascular outcomes trials in type 2 diabetes

Study	Drug	Comparator	Primary endpoint	Results
CANVAS	Canagliflozin	Placebo	Major adverse cardiovascular events, including CV death, non-fatal MI, and non-fatal stroke	2017
CARMELINA	Linagliptin	Placebo	Composite endpoint: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalization for unstable angina pectoris	2018
EXSCEL	Exenatide once weekly	Placebo	Composite endpoint: cardiovascular death, non-fatal MI, or non-fatal stroke	2018
REWIND	Dulaglutide	Placebo	Composite endpoint: cardiovascular death, non-fatal MI, or non-fatal stroke	2018
DECLARE-TIMI 58	Dapagliflozin	Placebo	Composite endpoint: CV death, MI or ischemic stroke	2019
CAROLINA	Linagliptin	Glimepiride	Composite endpoint: CV death, non-fatal MI (excluding silent MI), non-fatal stroke and hospitalisation for unstable angina pectoris	2019

CV cardiovascular, MI myocardial infarction